ATE276742T1 - Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung - Google Patents

Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung

Info

Publication number
ATE276742T1
ATE276742T1 AT98945216T AT98945216T ATE276742T1 AT E276742 T1 ATE276742 T1 AT E276742T1 AT 98945216 T AT98945216 T AT 98945216T AT 98945216 T AT98945216 T AT 98945216T AT E276742 T1 ATE276742 T1 AT E276742T1
Authority
AT
Austria
Prior art keywords
neutral
lamellar structure
total charge
particular complex
negative total
Prior art date
Application number
AT98945216T
Other languages
English (en)
Inventor
Alain Thierry
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9709698A external-priority patent/FR2766705B1/fr
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Application granted granted Critical
Publication of ATE276742T1 publication Critical patent/ATE276742T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT98945216T 1997-07-30 1998-07-30 Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung ATE276742T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709698A FR2766705B1 (fr) 1997-07-30 1997-07-30 Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR9710812A FR2766706B1 (fr) 1997-07-30 1997-08-29 Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
PCT/EP1998/005103 WO1999006026A1 (en) 1997-07-30 1998-07-30 Stable particulate complexes with neutral or negative global charge of lamellar structure

Publications (1)

Publication Number Publication Date
ATE276742T1 true ATE276742T1 (de) 2004-10-15

Family

ID=26233713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945216T ATE276742T1 (de) 1997-07-30 1998-07-30 Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung

Country Status (10)

Country Link
US (1) US6096335A (de)
EP (1) EP1001750B1 (de)
JP (1) JP2001511440A (de)
AT (1) ATE276742T1 (de)
AU (1) AU9260898A (de)
CA (1) CA2296394A1 (de)
DE (1) DE69826488T2 (de)
ES (1) ES2229534T3 (de)
FR (1) FR2766706B1 (de)
WO (1) WO1999006026A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259828A1 (en) * 1995-12-13 2004-12-23 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
WO1999059638A2 (en) * 1998-05-15 1999-11-25 Chiron Corporation Compositions and methods for the delivery of nucleic acid molecules
GB9905136D0 (en) * 1999-03-06 1999-04-28 Danbiosyst Uk Surface modification of lamellar particles
US6281005B1 (en) * 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
FR2803526A1 (fr) * 2000-01-12 2001-07-13 Biovector Therapeutics Matrices polymeriques amphiphiles et ioniques et derives de telles matrices
FR2803517A1 (fr) * 2000-01-12 2001-07-13 Biovector Therapeutics Sa Matrices plymeriques amphiphiles et ioniques et derives de telles matrices
ATE511400T1 (de) * 2000-03-03 2011-06-15 Genetronics Inc Nukleinsäure-fomulierungen zur genverabreichung
US20010046705A1 (en) * 2000-04-25 2001-11-29 Arnaud Debin Particulate complex for adminstering nucleic acid into a cell
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
US7037520B2 (en) * 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
WO2003106636A2 (en) * 2002-06-14 2003-12-24 Mirus Corporation Novel methods for the delivery of polynucleotides to cells
EP2353389B1 (de) 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Zusammensetzungen zur Behandlung von Erkrankungen
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
WO2006048329A1 (en) * 2004-11-05 2006-05-11 Novosom Ag Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
JPWO2023234250A1 (de) * 2022-05-30 2023-12-07

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5676954A (en) * 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
WO1991017424A1 (en) * 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
DE19605548A1 (de) * 1996-02-15 1997-09-04 Boehringer Ingelheim Int Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
DE69826488D1 (de) 2004-10-28
DE69826488T2 (de) 2005-12-01
WO1999006026A9 (en) 1999-04-29
JP2001511440A (ja) 2001-08-14
AU9260898A (en) 1999-02-22
EP1001750B1 (de) 2004-09-22
EP1001750A1 (de) 2000-05-24
US6096335A (en) 2000-08-01
ES2229534T3 (es) 2005-04-16
FR2766706B1 (fr) 2001-05-25
CA2296394A1 (en) 1999-02-11
WO1999006026A1 (en) 1999-02-11
FR2766706A1 (fr) 1999-02-05

Similar Documents

Publication Publication Date Title
ATE276742T1 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
DE69431587D1 (de) Skalierbares und effizientes Intra-Gebiet Mobile-IP Schema mit Tunneling
PY950041A (es) Compuesto de 1- fenil 3-dimetilamino- propano a procedimientos para su preparacion y a la aplicacion de estas sustancias en farmacologia
DE69516235D1 (de) Kreisbeschleuniger mit Ionenstrahlbeschleunigungsvorrichtung
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
ATE500815T1 (de) Neue suppositoriumsform mit säureempfindlichem wirkstoff
DE69429731D1 (de) Doppelpendel beschleunigungsmesser
FI954990L (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
ATE286718T1 (de) Temperatursensitive liposomale formulierung
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
FI955234L (fi) Entsyymidispersiot, niiden valmistaminen ja niitä sisältävät seokset
EA199900715A1 (ru) Липидные комплексы и липосомы совершенно нерастворимых комплексов платины
FI970551A7 (fi) Sementin kiihdytinseos
EP0729344A4 (de) Wirkstoffabgabesystem
DE59806485D1 (de) Herstellung von Ascorbylmonophosphaten
DE69328681D1 (de) Selbstschmierende polybenzimidazole enthaltende zusammensetzung
EP0679402A3 (de) Hybridgel, das eine biologisch aktive Substanz sekretiert.
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
EP0634938A4 (de) Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine.
TR199600931A2 (tr) Insaat malzemesi karisimi.
ATE228575T1 (de) Wirkstoffkombinationen
DE69433030D1 (de) Quadraturmischer
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon
NO920808D0 (no) Bis-bibenzimidazol-blanding
IT1214444B (it) Peptidi biologicamente attivi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties